预约演示

Chutes & Ladders—Former Celgene CEO Alles takes the top job at TORL

2024-01-12

高管变更临床1期上市批准并购

None

Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.

TORL taps new CEO

TORL BioTherapeutics

Mark Alles, who’s spent the better part of the last four decades in biopharma leadership roles, has been named chairman and CEO of TORL BioTherapeutics. He’s replacing Dave Licata, who co-founded TORL and helped design its drug development framework. Licata will stick around TORL as a board member and the company’s president, while also taking on a new role as its CFO.

TORL BioTherapeuticsber of TORL’s board for two years and was named its executive chair in late 2022. Before that, he spent more than a decade at Aventis Pharmaceuticals and then another 15 years at Celgene, culminating in a stint as its CEO from 2016 until its acquisition by Bristol Myers Squibb in 2019.

He’s taking the helm as TORL plans to begin a phase 2 trial of its lead antibody-drug conjugate candidate, TORL-1-23, targeting mulTORL BioTherapeuticshile, the company is actively enrolling patieTORLin phase 1 studies of a handful of other ADCs and monoclonal antibody therapTORL

Alles has rapidly realized TORLificant success in identifying novel cancer targets, developing first-in-class antibody-based therapies directed atAventis Pharmaceuticalsh the support of our world-claCelgenestors, has recently advanced multiple products into Phase 1 studies,” sBristol Myers Squibb.D., Ph.D., TORL’s scientific founder. “We have reached a major inflection point where our opportunity to generate value for patients, our investors and our team made it both possible and important for us to build on the great work Dave has done by adding and appointing Mark Alles as Chairman and CEO.” Release

Insitro installs first CMOTORL-1-23 cancers

Insitrocancer

Insitrotro inches closer to bringing its first artificial intelligence-discovered drug candidates into clinical trials, it has appointed its first-ever chief medical officer.

Insitronew role, S. Michael Rothenberg, M.D., Ph.D., will take charge of the company’s clinical development work, heading up translational biology and overseeing trial design and medical and regulatory affairs.

RotInsitro hails from Pfizer, where he spent the last four years carrying out similar responsibilities, including, most recently, as VP of early oncology development and clinical research. At the Big Pharma, he led early-phase trials of oncology and hematology therapies, including overseeing the initial first-in-human and proof-of-concept studies of the multiple myeloma drug now approved as Elrexfio. Release

Sanofi’s interim specialty care chief lands permanent role

SanofiPfizer multiple myeloma Elrexfio

SanofiFoard has temporarily filled the role of chief of Sanofi’s specialty care global business unit since September, when former head Bill Sibold hit the exit to lead Madrigal Pharmaceuticals as CEO. Now, Foard has claimed the title on a permanent basis and will also join Sanofi’s executive committee.

Sanofiec has been with Sanofi since 2017 and was bumped up from his former slot as head of the specialty care business in North America and U.S. country lead. Before that, he bounced from head roles in dermatology and respiratory to immunology, among other positions.

Foard is credited with overseeing launches of Sanofi andSanofieron’s Dupixent across multiple indications and more than 50 countries worldwide, work that will “help to Madrigal Pharmaceuticalsfirst- and best-in-class molecules we are preparing to launch in the coming years,Sanofirding to Sanofi CEO Paul Hudson. Release

> FDA commissioner RobeSanofiiff has selected his next chief of staff in Elizabeth “EJ” Jungman, who will leave her current role as the Center for Drug Evaluation and Research’s associate director for policy and director of the Office of Regulatory Policy. Jungman is taking over from Julie Tierney, who recently moved to a deputy director role at the FDA’s Center for Biologics Evaluation and Research. Release

> Rare disease specialist BioMarin has a new CSanofiAlexaRegenerony aDupixentpears to be shaking up his commercial team as the company announced its lead Jeffrey Ajer will leave the company by July. The disclosure, made via a short SEC filing, said Ajer would "step down" as the company's Sanofiive vice president and chief commercial officer in July and that the termination was “without cause." Fierce Pharma

> FDAgtime Affimed CEO Adi Hoess, M.D., Ph.D., is hanging up the gloves after 13 years at the helm. The company tapped CMO Andreas HarstCenter for Drug Evaluation and Researchle it searches for a successor. ReleaseFDA

> Ginkgo Bioworks selectedBioMarincutives from across the industry to make up its new Biopharma Advisory Board. The board now includes Kronos Bio CEO Norbert Bischofberger, Ph.D., global head of oncology and hematology at Novartis Jeff Legos, Ph.D., founding Alnylam chief John Maraganore, Ph.D, International Therapeutic Research Centers’ chief scientific officer Paolo Martini, Ph.D., IconOVir Bio head Mark McCamish, M.D., Ph.D., and former Kite Pharma CEO Christi Shaw. Release

> PMV Pharmaceuticals is shaking up its clinical team with the appointment of two new leaders of the clinical program for its lead candidate, PC14586, which is set to begin a phase 2 study this quarter. Deepika Jalota, Pharm.D., and Marc Fellous, M.D.—PMV’s chief development officer and senior VP of clinical development and medical affairs, respectively—are taking the reins from Leila Alland, M.D., who is stepping down to pursue other opportunities but will remain an advisor to PMV. Release

> Ginkgo Bioworkss now on the hunt for a new chief medical officer after Hans Moebius, M.D., Ph.D., stepped down to retire, effective JKronos Biobius, who is staying on as a senior scientific advisor to Athira, was appointNovartisn 2019, following a nearly 30Alnylamareer in biopharma that includInternational Therapeutic Research Centersn, Merz Pharmaceuticals, Novartis and more. ReleaIconOVir Bio Kite Pharma

> PMV Pharmaceuticals therapy developer Caribou Biosciences has named its first chief technology officer: Tim Kelly, who previously served as PC14586Oxford Biomedica Solutions and COO of Homology Medicines and led technical operations at Sarepta, Shire, UCB and Biogen. ReleasePMV

> Athira Pharmatup starter Flagship Pioneering has promoted from within to name four new origination partners: Kyle Chiang, Ph.D., Molly Gibson, Ph.D., Armen Mkrtchyan, Ph.D., and Jacob Rubens, Ph.D. In Athiranew roles, each will oversee a team tasked with creating and growing new biotech companies. ReleaseRodin Therapeutics Allergan Merz Pharmaceuticals Novartis

> Capstan Therapeutics tapped Ramin FarzCaribou Biosciencesbe chief medical officer, following stints at Ra Pharmaceuticals, Akebia Therapeutics, GilOxford Biomedica Solutionsently, RA CaHomology Medicinesbeen a venture partner since 2020Sareptaan also pUCBoted Biogen Arcinas, the biotech’s VP of corporate development since 2021, to the senior VP level. Release

> Celia Lin, M.D., stepped down from her post as chief medical officer of Vera Therapeutics. Taking over the role is Robert Brenner, M.D., who hails from Orionis Biosciences, while William Turner, formerly of Sierra Oncology, was named Vera’s chief development officer, with both appointments effective immediately. Release

> Capstan Therapeuticsrecently the chief commercial officer at Passage Bio, has been appointed president Ra PharmaceuticalscaAkebia TherapeuticsitGilead Sciences. Her career also includes stops at Sarepta Therapeutics, Sanofi Genzyme and ShCapstanlease

> Zura Bio has found a new president and chief operating officer in RobertVera Therapeuticshree-decade career in biopharma spans leadership roles at the nOrionis Biosciencesna Pharmaceuticals, Regeneron, InCarSierra Oncology Oncology, Daiichi Sankyo and Amgen. Meanwhile, Kiran Nistala, M.B.B.S., Ph.D., has been tapped as the biotech’s chief medical officer and executive VP of development. Release

> AbbVie’s retired CMO Rob Scott has a new gig as CMO and head Passage Biobionyx Pharma, where he will lead the team through pivotal trialCalliditas Therapeuticsandidate. Back at AbbVie, the medicaSarepta Therapeuticse SanofihGenzymeapprovals including Skyrizi and Rinvoq. Release

> Zura Bio selected Owen Hughes as its next CEO. Hughes—who held the top job at the biotech royalty aggregator on an interim basis for all of 2023—was previoPfizerEO of SArena PharmaceuticalsOnRegeneronndInCarda TherapeuticsceDaiichi SankyoTheraAmgencs. Release

> AbbVietics maker Pendulum Therapeutics tapped former Mayo Clinic medicaAbionyx Pharmam Perlman, M.D., as chief medical officer. Now-retired CMO Orvillesepsisrman, M.D., led the AbbVieion of Perlman as his successor. ReleaseSkyrizi Rinvoq

> XOMAracker Therapeutics bumped up its executive VP of early R&D, Sam Deutsch, M.D., Ph.D., to the CSO role. Deutsch has been with Nutcracker since its beginnings in 20Sail Bioill nCullinan Oncologythrough trialing its lead mRNA cIntarcia Therapeutics250. Release

> Central nervous sPendulum Therapeuticsesearch CorporaMayo Clinicted Tom Zoda, M.D. Ph.D., as CEO. Zoda came from Apex Innovative Sciences and CenExel clinical research, where he served as chief operating officer. Release